“Efficacy and Safety of Tislelizumab Plus Lenvatinib as First-Line Treatment in Patients with Unresectable Hepatocellular Carcinoma ”, mfm, vol. 35, no. 6, Jun. 2024, Accessed: Oct. 12, 2026. [Online]. Available: http://medicalforummonthly.com/index.php/mfm/article/view/4698